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ABSTRACT 
 
Tuberculosis is one of the leading causes of death due to infectious disease. The 
causative agent, Mycobacterium tuberculosis, is a facultative intracellular parasite with a 
slow regeneration rate. Though there is a decline in the overall TB incidence since 2005, 
the emergence of resistant strains that are impervious to existing treatment regimens 
make the discovery and development of new drug leads crucial. To this end, exploiting 
key differences between the biology of the host and the pathogen can generate novel 
lead molecules with minimal side effects. This thesis details the study of two proteins 
that are essential for the survival of M. tuberculosis (M.tb) but are not present in the 
host, making them potential drug targets.  
 
The first protein, IspD (2-C-methyl-D-erythritol-4-phosphate (MEP) cytidyl transferase), 
is a part of the non-mevalonate pathway for the synthesis of isoprenoids and catalyzes 
the condensation of MEP and cytidine triphosphate (CTP) to form 4-diphosphocytidyl-2-
C-methylerythritol (CDP-ME) and pyrophosphate (PPi). A medium-throughput enzyme 
assay was developed to identify inhibitors for this protein. It was screened against 3550 
compounds drawn from five different M. tb whole-cell active small molecule libraries 
generating a total of five hits. These molecules were then assessed for their potency 
against IspD as measured by their IC50, their activity against M. tb whole cells and their 
cytotoxicity. Of the five hits, two compounds inhibited M. tb whole cell growth at a 
concentration below 50 µM while exhibiting no general cytotoxicity to human dermal 
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fibroblasts (HDF). They each had an IC50 of 26.1 µM and 37.8µM and preliminary SAR 
studies were performed on the latter. These molecules could prove to be a viable starting 
point for the rational design of IspD inhibitors. 
 
The second protein, Wag31 is a cell division associated protein that regulates 
mycobacterial cell size and septum formation. Wag31 exhibited a propensity for gel 
formation both alone and in association with other cellular proteins. A purification 
strategy was developed to circumvent this tendency and generate soluble protein. It was 
found that mutations within the wag31 protein coding sequence conferred resistance to a 
whole-cell active small molecule (MIC99=6.25 µg/ml) in both M. tuberculosis and M. 
smegmatis. Moreover, all of the discovered mutations were clustered within the C-
terminal coiled-coil domain of the protein. It was established that this compound binds 
to Wag31 and seems to shift the equilibrium of the protein solution towards gel 
formation. The mutated protein does not form gel and seems to bind to the compound at 
a significantly reduced rate. To further confirm that Wag31 was indeed the target of this 
small molecule, whole cell viability assays were performed to establish whether the 
over-expression of Wag31 in M. smegmatis would shift the EC50 and MIC99 values. 
Wag31 over-expression reduced both the EC50 and MIC99 values providing further proof 
that Wag31 is the target for this compound. The compound appears to act by shifting the 
equilibrium of the protein towards a gelatinous state which proves inhibitory for cell 
growth. 
 
 iv 
 
ACKNOWLEDGEMENTS 
 
I would like to thank my committee chair, Dr. Sacchettini, and my committee members, 
Dr. Kunkel, Dr. Polymenis and Dr. Romo for their guidance and support throughout the 
course of this research. 
 
Thanks also go to my friends and colleagues, in particular Jennifer Tsai and Mallikarjun 
Lalgondar, and the department faculty and staff for making my time at Texas A&M 
University a great experience.  
 
Finally, thanks to my family for their encouragement and to my husband for his patience 
and love. 
 v 
 
NOMENCLATURE 
 
MESG   2-amino-6-mercapto-7-methylpurine riboside 
MEP 2-C-methyl-D-erythritol-4-phosphate 
IspD  2-C-methyl-D-erythritol-4-phosphate (MEP) cytidyl transferase 
CDP-ME 4-diphosphocytidyl-2-C-methylerythritol 
A Alanine 
R Arginine  
N Asparagine 
D Aspartate 
C Cysteine 
CTP Cytidine Triphosphate 
DSF Differential scanning fluorimetry 
DMSO Dimethyl sulfoxide 
DTT Dithiothreitol 
E Glutamate 
Q Glutamine 
G Glycine 
MC
2
7000 M.tb H37Rv BCG strain 
MC
2
4517 M. smegmatis competent cell strain  
EC50 Half maximal effective concentration of a drug 
H Histidine 
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IC50 Half maximal inhibitory concentration of a drug 
I Isoleucine 
IPTG Isopropyl-β-D-1-thio-galactopyranoside 
L Leucine 
K Lysine 
M Methionine 
MIC Minimum inhibitory concentration of a drug 
M. tb Mycobacterium tuberculosis 
F Phenylalanine 
PCR Polymerase chain reaction 
P                     Proline 
PPi Pyrophosphate 
RBS Ribosome silencing factor 
S Serine 
T Threonine 
W Tryptophan 
TB Tuberculosis 
Y Tyrosine 
V                                 Valine 
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CHAPTER I  
INTRODUCTION 
 
1.1 Tuberculosis: the disease and its challenges 
Tuberculosis (TB) is an airborne infection caused by various species of mycobacteria, 
primarily Mycobacterium tuberculosis, which claimed up to 1.4 million lives in 2010. It 
is a disease that affects the developing world with a disproportionate number of its 
victims being young people in their prime. Although there has been a steady decline in 
the TB incidence rate and death rate since 2005, the rise in the reported cases of drug-
resistant strains pose new challenges in the elimination of this pathogen [1]. The 
emergence of resistant strains of M. tb is both a function of the extensive duration of 
chemotherapy as well as the persistent nature of the infection. Some infections are 
known to spontaneously reactivate after 6 months of medical intervention [2]. The 
current treatment involves the administration of Isoniazid (INH), Rifampicin (RIF), 
Pyrazinamide (PZA) and Ethambutol (EMB) in combination for 2 months followed by 4 
months of INH and RIF [3]. Multi-drug resistant (MDR) TB strains exhibit resistance to 
at least INH and RIF which necessitates treatment with second line drugs like 
fluoroquinolones, Ethionamide (ETH), Kanamycin, Capreomycin and D-cycloserine [2]. 
This can not only increase the cost of treatment (200 fold) and its side effects; MDR TB 
chemotherapy can last up to 2 years [4]. According to the WHO Global TB Control 
Report of 2011, MDR TB accounted for 650,000 of the TB deaths in 2010 [1]. 
Resistance to fluoroquinolones and one or more of the other second line drugs in 
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addition to the core TB drugs has been reported in at least 77 countries and is 
categorized as XDR (eXtremely Drug Resistant) TB by the WHO [5]. There have been 
three reported outbreaks of TDR (Totally Drug Resistant) TB so far: in Italy in 2007 [6], 
in Iran in 2009 [7] and in India in 2011 [8]. The most effective treatment for TB was 
introduced half a century ago and by 2012, resistance to all the existing drugs has 
already been documented. It is clear that M. tb is a formidable opponent and 
understanding its biology and isolating new drug targets to overcome the existing 
resistant mutations is of the greatest importance. 
 
A 2008 in silico high throughput target identification study revealed potential M. tb drug 
targets by selecting for a range of properties including but not limited to: essentiality, 
absence of a homolog in the host and absence of homologs in the proteome of the gut 
flora. The proteins described in this proposal are two of the enzymes identified by this 
method making them valuable drug targets [9].  
 
1.2 IspD (2-c-methyl-d-erythritol-4-phosphate (MEP) cytidyl transferase) 
The non-mevalonate pathway for the synthesis of isoprenoids 
Isoprenoids are a large and diverse group of organic compounds that are derived from 
five carbon isoprene units. These naturally occurring lipids are of great physiological 
significance; they are involved in electron transport, photosynthesis, regulating gene 
expression and signal transduction. They are essential for the formation of membranes 
and are components of various hormones, vitamins, scents and pigments [10]. In 
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Mycobacteria, they are involved in the development of the cell wall, including the 
synthesis of mycolic acids and lipoarabinomannan [11]. Isopentyl pyrophosphate (IPP) 
and dimethylallyl pyrophosphate (DMAPP) are the precursors to all biological 
isoprenoids. The high profile of isoprenoids in biological processes makes the synthesis 
of these precursors an essential metabolic event. There are primarily two cellular 
pathways that are involved: the Mevalonate pathway and the Non-mevalonate/1-deoxy-
d-xylulose-5-phosphate (DOXP) pathway/2C-methyl-d-erythritol-4-phosphate (MEP) 
pathway with the latter being a relatively recent discovery [12, 13]. For the longest time, 
it was assumed that the mevalonate pathway was the only route toward isoprenoid 
precursors. It is now known that plant chloroplasts, algae, cyanobacteria, prokaryotes 
and apicomplexan parasites utilize the non-mevalonate pathway [14]. 
 
The intermediates generated decide the difference between the two pathways and their 
names: the mevalonate pathway proceeds via the synthesis of mevalonate while the key 
intermediate in the non-mevalonate pathway is 2C-methyl-d-erythritol-4-phosphate 
(MEP). (Figure 1) 
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Figure 1. Schematic representation of the mevalonate and non-mevalonate pathways 
 
The MEP pathway proceeds via seven enzymatic reactions that convert pyruvate and 
glyceraldehyde-3-phosphate to IPP and DMAPP (Figure 1). The first step, catalyzed by 
the enzyme DXS (1-deoxy-D-xylulose 5-phosphate synthase), condenses pyruvate and 
glyceraldehyde-3-phosphate to form DOXP (1-deoxy-D-xylulose 5-phosphate). 
Mevalonate Pathway MEP Pathway 
IspH 
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Subsequently DOXP is converted into MEP (2-C-methyl-D-erythritol-4-phosphate) by 
DXR (1-deoxy-D-xylulose 5-phosphate reductoisomerase) via the oxidation of NADPH. 
IspD transfers the cytidyl moiety from CTP to MEP to form CDP-ME. The IspE enzyme 
facilitates the addition of a phosphate to CDP-ME from ATP forming CDP-MEP. CDP-
MEP undergoes three more enzymatic steps, (catalyzed by IspF, IspG and IspH) that 
involve the removal of the nucleotide followed by two consecutive dehydration reactions 
to form IPP and DMAPP [14]. 
 
All of the enzymes in the MEP pathway have been studied extensively. The E. coli 
protein structures have been solved for all the enzymes except IspG [14, 15]. In case of 
the latter, the Thermus thermophilus [16] and Aquifex aoelicus [17] homologous protein 
structures have been solved. M. tuberculosis protein structures have been solved for 
DXR [18], IspD (PDB ID: 30KR) and IspE [19] and the Mycobacterium smegmatis IspF 
[20] structure has been solved. 
 
Since the non-mevalonate pathway is entirely absent in the host (in this case Homo 
sapiens) and the host and pathogen use different pathways to synthesize isoprenoids, the 
enzymes of this pathway have long been considered attractive targets for drug 
development [14, 21]. 
 
In M. tuberculosis, the essentiality of this pathway has been established [22] and 
provides a hitherto unexplored avenue for drug development. It also furnishes an 
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alternate route to attack the cell wall which is the target of time tested drugs like INH, 
ETH and EMB [2]. 
 
One of the enzymes in the MEP pathway, DXR, is the well-known target of the 
Plasmodium drug Fosmidomycin, but is not essential for the growth of M. tuberculosis 
in vitro [23]. In addition, Fosmidomycin cannot penetrate the thick cell wall of the 
pathogen. This makes a strong argument for the development of alternate enzyme targets 
along this pathway such as IspD. 
 
The IspD enzyme and its value as a drug target 
Genetic analysis determined that IspD is encoded by the M. tuberculosis gene, Rv3582c, 
which showed 31% identity to the amino acid sequence of the E. coli homolog [24]. It 
shares the highest sequence similarity to the M. bovis gene (99%) with sequence 
similarity dropping drastically across genera. This gene is believed to be part of a 
bicistronic operon which also carries the IspF gene (Rv3581c) [22]. The means by which 
IspD gene expression is regulated are not well characterized.  
 
Rv3582c is 696 bp long and encodes a polypeptide chain comprising 234 amino acids 
with a molecular weight of 26 kDa. IspD is a cytosolic protein and is known to be a 
functional dimer [24]. 
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IspD has been demonstrated to be essential for the in vitro survival of M. tuberculosis 
both by transposon site hybridization (TraSH) [23] and the inability to isolate a non-
functional mutant in H37Rv using gene switching analysis [24]. This further enhances 
the enzyme’s appeal as a drug target. 
 
IspD catalyzes the transfer of the cytidyl moiety from CTP to MEP, thereby forming 
CDP-ME and releasing PPi and is therefore categorized as a transferase (Figure 2). The 
reaction is thought to be sequential with CTP binding first followed by MEP. A 
magnesium ion is required to stabilize the pentacoordinate phosphate transition state that 
results from the nucleophilic attack of the MEP phosphate on the α-phosphate of the 
CTP [25]. 
 
 
Figure 2. Schematic representation of the reaction catalyzed by IspD 
 
The kinetics of IspD has been the focus of various studies. There is a discrepancy in the 
values published by the various groups which could be attributed to the different assays 
and reaction parameters used to measure enzyme activity [24, 26, 27]. However, a 
repetition of the experiments in our lab re-confirmed a Km of 43.5 for MEP and 45.5 for 
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CTP as reported in the study by Björkelid et al [27]. IspD is active over a broad pH 
range and the essentiality of a divalent ion was demonstrated by the fact that addition of 
EDTA completely extinguished its cytidyl transferase activity. It shows better activity 
with magnesium than with other ions, which is consistent with other IspD homologs 
[24]. 
 
The crystal structure of M. tuberculosis IspD has been solved in our lab (courtesy Dr. 
Manchi Reddy). We have submitted to PDB the structures of the apo-protein at a 
resolution of 2.4 Å (PDB ID: 30KR), protein bound with the substrate, CTP, at 2.1 Å 
(PDB ID: 3Q7U) and protein with product, CDP-ME, bound at 2 Å (PDB ID: 3Q80). 
We have been unable to obtain crystals with MEP bound at the active site which is 
consistent with the proposed mechanism which requires CTP binding first in order to 
recruit MEP to the active site [25]. The structure showed significant similarity to the E. 
coli protein, however, there were some significant differences between active site 
residues that made it more flexible and may help explain the difference in the reaction 
kinetics between the two homologs. 
 
1.3 Wag31 
 DivIVA family of proteins 
The DivIVA protein is highly conserved in gram positive bacteria. It is a cell division 
and chromosome partitioning associated protein (NCBI Pubmed Conserved Domain 
Database). In rod shaped cells, it is known to localize to the cell poles and is believed to 
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act as a scaffold for other proteins during cell wall biosynthesis and cell division. It is 
known that DivIVA localization at the poles is due to its recognition of the spherical 
inward curve of these cells near the poles compared to the remaining portion (which 
maintains a cylindrical curve which is less sharp). Furthermore, it has been postulated 
that it is this same negative curvature that guides its localization to septum formation 
sites during cell division [28]. The loss of DivIVA causes abnormal morphology in these 
cells, though the nature of this abnormality varies between different species. The 
proteins of this family also exhibit a pronounced tendency to form multimers [29]. It has 
been suggested that this oligomerization plays a key role in its localization at the poles of 
rod-shaped cells [30]. 
 
As of April 2014, a single structure has been solved for this family of proteins: that of 
the Bacillus subtilis DivIVA N-terminal domain. Combined with a low resolution 
structure of the C-terminal domain, a model for the full length protein structure has been 
proposed [29]. The extremely limited data in this regard ensures that any new structural 
information regarding members of this family of proteins will be highly valuable. 
 
Wag31: essential and enigmatic 
Wag31 is encoded by Rv2145c of the M. tuberculosis H37Rv strain. It encodes a 
polypeptide that is 260 amino acids long with a molecular weight of 28.2 kDa and was 
found to be essential by TraSh [23]. The M.smegmatis ortholog shows 78% sequence 
identity and 85% similarity over the entire length of the M.tb protein sequence. Attempts 
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to disrupt the M. smegmatis wag31 gene were unsuccessful which supports the 
importance of this protein for cell survival in Mycobacteria [31]. 
 
The link between Wag31 and cell morphology was first illuminated during an 
investigation of the function of the PknA and PknB threonine kinases which were shown 
to regulate cell morphology. Wag31 was identified as one of the potential cellular 
substrates of the PknA kinase and the phosphorylation was found to occur on the 
threonine 73 residue. It was later determined that phosphorylation state of Wag31 
regulates the morphology of the M.tb cell. The current hypothesis maintains that PknB 
phosphorylates PknA in response to some external stimuli and that the latter protein then 
proceeds to phosphorylate Wag31. The means by which Wag31 regulates cell 
morphology is currently not known [32].  
 
Protein structure prediction using MultiCoil algorithm [33] indicates that Wag31 like 
other DivIVA family proteins has a coiled-coil domain at both C- and N- terminals 
interspersed by a highly variable region that contains the phosphorylation site [32].  
 
Using M. smegmatis as a model, it has also been confirmed that Mycobacterial Wag31 
like other DivIVA family proteins localizes at the poles (for the bulk of the cell cycle) 
and the sites of septum formation (at the time of cell division). What is unusual about 
this enzyme is that overexpression often leads to accumulation of the enzyme along the 
cylindrical walls of the cell, stimulating the formation of branches. This seems to 
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contradict the general assumption that DivIVA family protein localization is based on 
the recognition of negative cell wall curvature. Overexpression can also lead to the 
formation of bowling-pin shaped cells with 80 fold the volume of a regular cell and an 
accumulation of Wag31 at the bulbous end. Cell wall biosynthesis and cell elongation 
were accelerated in the regions were Wag31 accumulated, while septa formation was 
inhibited in that vicinity. The irregular septa formation and cell volume interfered with 
regular cell division and reduced cell viability. The cell is unable to tolerate this 
phenotype for long and self-regulates Wag31 expression in order to restore the regular 
cell morphology. Within 5 days of transformation of the overexpression plasmid, a 
marked decrease in Wag31 expression was observed [31]. 
 
Recently, it has been proposed that the differential growth between the phosphorylated 
and dephosphorylated forms of Wag31 is due to increased peptidoglycan synthesis in the 
regions where Wag31 is localized. This explains the rod shape of the cells when they are 
growing normally as well as the branching and bowling pin shaped cells in the 
overexpression strains. The exact nature of its interaction with peptidoglycan 
biosynthesis proteins remains to be elucidated [34, 35].  
 
Research indicates that Wag31 expression is positively regulated by the stringent 
response, suggesting that it may be involved in virulence [36]. Data also suggests that it 
helps the pathogen withstand oxidative stress [37]. 
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Wag31 is thus a protein that performs a diverse range of important functions in 
mycobacteria. Combined with its essentiality for mycobacterial survival and the absence 
of a homolog in the host, it constitutes an ideal target for drug development.  
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CHAPTER II 
SMALL MOLECULE SCREENING OF IspD: RESULTS 
 
2.1 The development of an assay to measure IspD enzyme activity 
 IspD was purified according to the protocol previously established in the lab. The 2-
amino-6-mercapto-7-methylpurine riboside (MESG) assay for the detection of 
phosphates was used to detect enzyme activity (Figure 3). Protein, substrate and coupled 
enzyme concentrations were optimized to maximize signal to noise ratio. It was 
observed that at 60 nM (protein conc.), even with substrate concentrations at or near Km 
values, the read-out was high and did not fluctuate sharply (Figure 4a).  It was decided to 
do all further studies using this concentration. IPPase and PNP concentrations were 
optimized next. IPPase concentration was finalized to 0.1 U/ml and it was determined 
that PNP concentration at 0.06 U/ml gave the greatest signal to noise separation with the 
minimal deviation in absorbance values (n=10) (Figure 4b).  
 
This higher separation in absorbance also involved using a near saturating concentration 
of CTP. Since the reaction mechanism requires the binding of CTP before MEP can 
bind, it was proposed that a higher occupancy of CTP in the enzyme active sites would 
be required to propel the reaction forward at a reasonable rate. It has also been advised 
that in the case of multi-substrate reactions, the mechanism of action may determine the 
substrate concentrations that are optimal for HTS screening [38]. MESG concentration 
was optimized to 200 µM. The assay was then monitored over time and it was 
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determined that it reaches saturation at 15 minutes post substrate addition (Figure 5, all 
experiments were performed in duplicates). 
 
 
 
 
Figure 3. MESG assay for the detection of pyro phosphate 
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Figure 4. Optimization of IspD enzyme assay. (a) IspD enzyme concentration was varied initial and 
end point absorbance was recorded at 360 nm. The graph represents the variation of endpoint 
absorbance as a mean ±SD for three separate experiments. (b) Assay performed with 0.06 U/ml PNP 
showed maximum spread in absorbance values between the reactions performed with and without 
IspD and is represented as mean ±SD for three separate determinations. 
 
 
The final assay was performed in 50 mM Tris pH 7.5 supplemented with 1 mM MgCl2. 
60 nM ISPD, 0.1 U/ml IPPase, 0.06 U/ml PNP and 200 µM MESG was used. 1 µl of 
DMSO was added as a control since all the compound libraries were dissolved in 
DMSO. The reaction was initiated by the addition of the substrates (50 µM MEP and 
100 µM CTP). The total reaction volume was 50 µl. The reaction was monitored by 
reading the absorbance at 360 nm. 
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Figure5. IspD enzyme activity monitored over a 15 minute interval. The experiments were done in 
triplicates and repeated twice. Two of the representative curves are shown above. 
 
2.2 The adaptation of the MESG assay for IspD to a 384-well format 
In order to test the response of the assay developed, it was performed in a 384 well plate 
by filling the entire plate with 4 different reaction conditions: the optimized assay, assay 
without IspD, assay without substrate and assay without dye. These were distributed on 
the plate so as to account for any positional effects that may exist. None were observed 
and it was noticed that the assay without IspD/substrate generated the least signal. Since 
there were no known inhibitors of M.tb IspD and the available herbicide inhibitors of 
Arabidopsis thaliana IspD did not show inhibition when tested, assay without substrate 
was used as positive control. (This was also convenient for CyBi Robot programming 
compared to the assay without IspD). 
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Subsequently, a program was written for the CyBi®-Well vario and a screen was 
performed against a randomly selected plate in the SAC1 diversity library. The final 
compound concentration was 20µM. The compounds were incubated for 5 minutes 
which was a compromise between MESG dye decay and CTP hydrolysis rates in real 
time and the need to pick as many different kinds of lead molecules as was possible 
through the screen. The program was further optimized to give the result shown below 
(Figure 6).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Scatter plot representing IspD screened against SAC1 diversity library plate no. 6085 
 
 
 
 
(Figure 7) 
 18 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Scatter plot representing IspD screened against SRI library plate 2 
 
Based on the above results, it was decided that the initial time=zero absorbance would be 
subtracted from all the absorbance readings in order to have the baseline at zero. Since 
the spread of the absorbance values were within +3x standard deviation on average 
(though definitely skewed in this case toward the higher values), it was determined that 
20 µM was a fitting concentration to perform the screen. For the initial library, the hit 
rate would be defined as Hit = Mean-(3x standard deviation).  
 
The first library to be screened was the SRI library which was developed by the 
Southern Research Institute. All the compounds in this library are active against the 
H37Rv strain of M. tuberculosis. The library is enriched for kinase inhibitors, which 
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reduces the available diversity to an extent [38]. The result from a typical plate is shown 
above (Figure 7). 
 
2.3 The screening results 
1241 compounds were screened and the hits as characterized by the previously 
established definition were retested at 40, 20 and 10 µM in triplicate. 14 of the original 
hits could be re-confirmed as true hits. These were subsequently screened for IPPase and 
PNP inhibition using the secondary screen. 12 of the hits dropped out at this stage and 2 
compounds could be confirmed as true IspD inhibitors. Since this was the first library 
screen performed, 10 compounds (which were not hits in the original screen) were 
selected from each plate and re-tested in duplicate at 20 µM concentration to identify the 
incidence of false negatives. None of the selected compounds showed inhibition. It was 
then decided to proceed with all future libraries using the same strategy. 
 
The next library to be screened was a section of the SAC1 50,000 compound diversity 
library. This section was comprised entirely of ChemBridge Hit2Lead® supplied 
compounds. Not all compounds in this selection were whole cell active; nevertheless, 
they were easy to procure for further studies. The hits from the SRI library had presented 
some challenges on this front. However, this was a temporary deviation from the 
established program and the whole cell activity for all of these compounds was available 
in our lab. 2112 compounds were screened, 20 re-tested and 3 of these were confirmed 
as true IspD inhibitors. 
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The Sac1 whole cell hit library was screened next. 1667 compounds were screened, 14 
re-tested and 3 were true IspD inhibitors. 2 of these overlapped with the SAC1 
ChemBridge Hit2Lead® library screen hits. 
 
Three more whole cell active libraries were tested: the Natural Product library from 
Malaysia (145 compounds), the Herbicide library (52 compounds) and the NIH clinical 
collection (445 compounds). None of these libraries yielded any hits. The six hit 
compounds from the various screens are shown below (Figure 8). 
 
     
 
 
Figure 8. Final hits from the IspD enzyme screen  
SRIa SRIb SAC1a
aaaa 
SAC1d SAC1c SAC1b
vb 
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2.4 Determination of IC50 
The IC50 was determined for the hits validated. All the compounds were purchased from 
ChemBridge Corporation, USA, save one SRI library hit molecule (SRIa). The latter was 
synthesized in our lab by Dr. Vijay Gawandi. Dose response curves were plotted and 
IC50 calculated using the data fitting algorithm on CDD (Figure 9a, 9b, 9c and 9d). SAC1 
d had an IC50 that was above 50 µM and since it was similar to SAC1b, is not shown 
here. In case of SRIb, the fresh compound did not re-test and mass spectroscopy 
suggests that the compound may have been degraded in the screening plate. Attempts to 
isolate the active species were unsuccessful. 
 
        
 
Figure 9. Dose response curve for (a) SRIa (b) SAC1c (c) SAC1a (d) SAC1b. Dose response was 
performed in triplicates at 10 different concentrations. The curves were calculated using mean over 
three separate determinations. 
SRIa  
IC50 = 26.1 M 
(a) 
S
CH3
O
NH
N+O
O-
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Figure 9. Continued 
(Figure 8) 
SAC1c 
IC50 = 37.8 M 
(b) 
SAC1a 
IC50 = 22.1 M 
H3C O
O
N
H
O
S
S
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N
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Figure 9. Continued 
 
2.5 Whole cell assays 
The hits were screened against M. tuberculosis MC
2
7000 cells and all the compounds 
were found to be active except SAC1a (confirming previous results from our lab). It was 
also observed that SAC1b could reduce cell viability at concentrations several fold lower 
than its IC50. This seemed to indicate that IspD may not be its main cellular target 
(Figure 10). 
 
The MICs for SRIa and SAC1c however were consistent with the dose response data and 
we decided to give these compounds top priority.  
SAC1b 
IC50 = 20.6 M 
N
O
O
Cl
Cl
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Figure 10. MC
2
7000 growth inhibition by IspD screen hits. Whole cell assays were performed in 
duplicates and repeated twice. Varying concentrations (100-1.56 µM) of compound were used. A 
representative plate is shown above. MIC99 was calculated as average of two separate 
determinations. 
 
 
The compounds were also screened against the human primary HDF cell line (Human 
Dermal Fibroblasts) using the Resazurine assay to assess cytoxicity. Mitoxantrone was 
used as a positive control while DMSO was used as a negative control. Mitoxantrone is 
routinely used in the lab for this purpose and kills cells completely at less than 100 µM 
concentration. The completion of the assay revealed that SAC1b had an MIC90 of 6.25 
µM. This established that SAC1b was generally cytotoxic and was subsequently 
eliminated from the list of hits to be further characterized. (Figure 11) 
 
SAC1c 
SAC1b 
SAC1a 
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Figure 11. Human dermal fibroblasts growth inhibition by IspD screen hits. Cytotoxicity was 
determined by staining with resazurin. The experiments were performed in duplicates once at 
varying concentrations (100-6.25 µM). 
 
2.6 Exploring chemical space with structural analogs 
A structure search was performed on SciFinder® using an 85% similarity threshold. 14 
hits were obtained for SAC1a with 5 of these available commercially (Figure 12a, 12b, 
12c, 12d and 12e).  The enzyme assay was performed against all 5 compounds and none 
of them gave better activity than the initial hit, SAC1a. Compounds 12b and 12c showed 
minimal activity at 100 µM and 12e had an IC50> 50µM. Compound 12a exhibited 25% 
of the inhibition shown by the original compound, SAC1a, at the same concentration 
while 12d had the same activity and dose profile as the original compound. This seems 
to indicate that substitution at the ortho-position on the benzene ring is not favored. It 
also suggests that the length of the chain at the meta-position on this ring does not 
influence binding.  
 
 
Compound 100      50         25       12.5     6.25       100       50        25        12.5      6.25         Conc (µM) 
SAC1c 
SAC1b 
SRIa 
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Figure 12. Hits obtained using structure similarity search on Scifinder. 
 
2.7 Crystallization trials 
Attempts were made to obtain native, CTP-bound and protein-inhibitor co-crystals. 
Native and CTP co-crystals were set up in the original conditions optimized in our lab in 
sitting drop, hanging-drop and micro-batch experimental set-ups (Figure 13d). The 
initial crystals which diffracted very poorly were crushed and used as seeds for future 
experiments. Attempts were also made to soak some of the older crystals set up by 
various members of our lab. These were densely layered and difficult to separate. The 
few layers that could be isolated diffracted very poorly (4 Å at Advanced Photon Source, 
Chicago). 
(d)  
(a) (b) (c) 
(e) 
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IspD was incubated with the inhibitors and screened against the 8 crystallization screens 
available in the lab. This was done (a) after a single-step nickel (Ni) column purification, 
(b) after 2-step purification with Ni column followed by gel filtration and (c) after TEV 
cleavage with single step and two-step purification. Multiple protein concentrations, 
compound concentrations and protein: reservoir ratios were used to set up plates. After 2 
months, a hit was obtained in the condition which has 0.1 M imidazole and 1 M sodium 
citrate. This was non-cleaved protein that had been subjected to the 2 step purification 
and concentrated to 8 mg/ml and incubated with 5 mM of compound. This crystal 
diffracted to 3.8 Å (Figure 13a). Efforts were made to improve the crystal by using the 
detergent and additive screens. Using the detergent C8E5 improved the crystal quality 
slightly and it could now diffract up to 3.2-3.4 Å (Figure 13b) and it now appeared in 
little more than a fortnight. Further attempts to improve the quality using the ionic liquid 
screen, dehydration, annealing and cross-linking have not succeeded so far. 
 
Attempts were also made to soak some of the CTP co-crystals we had managed to 
reproduce recently (Figure 13c). They were extremely fragile and did not respond well 
to being soaked in the mother liquor, DMSO or 1-50% DMSO in mother liquor. 
Different solvents like acetonitrile, isopropanol and ethanol were also used, solo or in 
combination with mother liquor. The crystals disintegrated even with 3-5 minute soak 
times.  
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Figure 13. IspD crystals and diffraction patterns. (a) IspD-SRIa co-crystal, (b) IspD-SRIa 
diffraction pattern (3 min exposure), (c) IspD-CTP co-crystals and (d) IspD apo-crystal.   
 
 
 
 
 
(a) 
(b) 
(c) (d) 
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CHAPTER III  
PURIFICATION AND CHARACTERIZATION OF Wag31: 
RESULTS 
 
3.1 Purification 
The wag31 gene from M. tb was amplified and cloned into pET28 (b) TEV vector and 
transformed into the E.coli BLD1 (DE3) protein expression strain. Expression tests were 
conducted at multiple temperatures (37°C, 24°C and 16°C). Maximum expression was 
observed after induction at 37°C. Small scale expression tests determined that the protein 
was in the soluble fraction (Figure 14). 
 
Although multiple attempts were made to purify the protein, every attempt to lyse it 
immediately resulted in the formation of a very viscous solution which solidified to a 
jelly-like consistency on spinning in the high speed centrifuge. 
 
The use of 6 different detergents did not resolve the consistency issue. A typical lysate 
and supernatant sample are shown below (Figure 14). Almost all the protein is in the 
soluble fraction. Purification using acidic or basic buffers and high temperature 
purification (37°C, 42°C) was attempted next. The final purification strategy involved 
lysing the cells using a sonicator, heating the lysate at 42°C for 5 minutes followed by 
spinning down in the high speed centrifuge at 16000 rpm for an hour. The supernatant 
was loaded on a Ni column and purified by the application of an imidazole gradient (0-
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500 mM imidazole) (Figure 15). Western blot analysis confirmed the protein was hexa-
His Wag31 (Figure 16). 
 
 
 
Figure 14. SDS gel seperation of lysate and supernatant fractions of Wag 31 overexpressed in E.coli 
BL21 (DE3) cells. The gel is representative of three separate experiments.  
 
 
 
 
 
Figure 15. SDS gel separation of Ni affinity chromatography wash and gradient fractions obtained 
on purifying Wag31. The pooled fractions are enclosed in the box. The gel image is representative of 
three separate experiments. 
Wag31 
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Figure 16. Western blot analysis of Wag31 Ni chromatography fractions probed with anti-His 
antibody from mouse conjugated with alkaline phosphatase. Substrate was added to trigger the 
colorimetric reaction. Image is representative of two separate experiments. 
 
 
Several different constructs of wag31 were purified after the process was optimized. The 
results are summarized Table 1: 
 
             Construct                       Purification Result 
1 Wag31 WT pet28(b)TEV   Can be purified, forms gel on 
concentration 
2 Wag31T73A(dephosphorylated) 
pet28(b)TEV 
  Can be purified, forms gel on 
concentration 
3 Wag31T73E(phosphorylated) 
pet28(b)TEV 
  Can be purified, forms gel on 
concentration 
4 Wag31 WT (expressed in M. 
smegmatis) p1602-dest 17 
  Can be purified, forms gel on 
concentration 
5 Wag31 M. smegmatis ortholog MCSG7  Cannot be loaded on the affinity 
column, forms a strong thick gel on lysis 
 
 
Table 1. Summary of Wag31 constructs and the behavior of the corresponding proteins on 
purification. Representative of three separate purifications. 
 
Wag31 
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 Construct Purification Result 
6 Wag31 9-96 aa (C truncation) MCSG7 Can be purified, forms gel on 
concentration 
7 Wag31 97-260 aa (N truncation) 
MCSG7 
Can be purified, Most of the protein 
remains in gel fraction 
8 Wag31 128-260 aa (N truncation) 
MCSG7 
Can be purified, Most of the protein 
remains in gel fraction. Pure protein 
spontaneously forms gel 
 
Table 1. Continued 
 
 
3.2 Resistant mutant studies 
During the course of this work, a parallel study in the lab led to the isolation of 
MC
2
7000 (M. tuberculosis BCG vaccine strain) mutants which were resistant to 2 
compounds in the SRI compound library (Figure 17). Subsequent whole genome 
sequencing established that these mutations were in the wag31 protein coding region. 
 
 
                   
 
 
 
Figure 17. Compounds that led to the isolation of MC
2
7000 resistant mutants with point mutations 
in the Wag31 protein coding region (a) Compound A and (b) Compound B 
(a) (b) 
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The mutations identified in the initial study were all point mutations in the C- terminal 
coiled-coil domain of the protein. These include: I194L, E206G and R202C (Data 
Courtesy: Dr. Inna Krieger and Dr. Thomas Ioerger). Furthermore, a similar study on M. 
smegmatis yielded a mutant resistant to compound A. Whole genome sequencing later 
established this mutation was equivalent to the E206G mutation in M.tb (In this case 
E216G) (Data courtesy: Ryan Hughes). 13 more MC
2
7000 mutants resistant to 
compound A were isolated. Genomic DNA was extracted from these mutants and sent 
for whole genome sequencing. All of the colonies isolated, had point mutations in the C 
terminal coiled-coil domain of the wag31 protein coding sequence (Table 2).  
 
    
Colony No. Mutations 
1 I194L 
2 K179E, I194L 
3 I194L 
4 Q201R 
5 E206G 
6 I194L 
7 E206G 
8 D186G 
9 Q201R, D181N 
10 E206G 
11 E206G 
12 K190N 
13 I194L, R157C, K127E 
 
 
Table 2. List of MC
2
7000 compound A resistant mutants with the corresponding mutations 
identified. Thirteen separate colonies were picked to perform genomic sequencing. 
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The above mutations are mapped in the protein coding sequence in bold red (C-terminal 
coiled-coil is underlined): 
 
MPLTPADVHN VAFSKPPIGK RGYNEDEVDA FLDLVENELT RLIEENSDLR 
QRINELDQEL AAGGGAGVTP QATQAIPAYE PEPGKPAPAA VSAGMNEEQA 
LKAARVLSLA  QDTADRLTNT AKAESDKMLA DARANAEQIL GEARHTADAT 
VAEARQRADA MLADAQSRSE AQLRQAQEKA DALQADAERK HSEIMGTINQ 
QRAVLEGRLE QLRTFEREYR TRLKTYLESQ LEELGQRGSA APVDSNADAG 
GFDQFNRGKN 
 
It was also noted that the E206G and I194L mutations occurred at a higher frequency 
than the other observed mutations (4 in 10 and 5 in 10 respectively). 
 
3.3 Binding studies  
To establish whether Wag31 was indeed the target of compound A, various binding 
studies were conducted. Intrinsic fluorescence was measured. Since Wag31 does not 
contain any tryptophans, the signal was quite low. However, there was a reduction in 
fluorescence in the presence of increasing concentration of compound (Figure 18). 
 
Next, the purified protein was concentrated in the presence of 10 molar excess of 
compound A. Since the compound was colored (yellow), it was possible to see a clear 
difference between the compound bound to protein in the concentrator compared to the 
flow through. Wag31 forms a gel at high protein concentration and it was observed that 
in the presence of the compound this gel too was colored yellow (Figure 19). 
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Figure 18. Intrinsic fluorescence measurement of Wag31 (10 M). Image is representative of three 
separate experiments. 
 
 
      
 
Figure 19. Concentration of Wag31 with 10 M excess of compound A. (a) Concentrator with 
compound A bound to protein in the upper compartment and flow through in the lower 
compartment. (b) Gel localized on the concentrator membrane. (c) Comparison of gel formation in 
the absence and presence of compound A. All the above experiments were performed at least thrice. 
Compound conc. 
0.75 M 
500 M 
(a) (b) (c) 
 36 
 
3.4 Whole cell viability assays 
To further confirm that Wag31 was indeed the target of compounds A and B, a whole 
cell viability assay was performed using the M. smegmatis MC
2
4517 strain (Figure 20). 
This strain is routinely used for the overexpression (OE) and purification of TB proteins, 
including Wag31. If overexpression of Wag31 could induce a shift in the EC50 or MIC99 
values, it would provide further proof that Wag31 was indeed the cellular target of these 
compounds. Both the wild-type MC
2
4517 as well as MC
2
4517 overexpressing M. 
tuberculosis Ribosome Silencing factor (RSF) were used as controls.  
 
It was observed during the course of the experiment that cells over-expressing Wag31 
grew at half the rate of the control strains. This was taken into account while reading the 
plates. Additional readings were taken every day for a week until the values leveled off. 
 
 
 
 
Figure 20. Whole cell growth inhibition assay (a) MC
2
4517 (b) MC
2
4517 RSF OE (c) MC
2
4517 
Wag31 OE. The images are representative of two separate experiments. 
(a) 
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Figure 20. Continued 
 
 
 
 
 
 
(b) 
(c) 
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 Compound Cell Line EC50 (µM) MIC90 (µM) MIC99 (µM) 
     
Compound A MC
2
4517 WT 5.51±0.015 6.38±0.020 7.48±0.070 
Compound A MC
2
4517 Ribosome 
Silencing Factor OE 
5.24±0.015 5.79±0.015 6.45±0.020 
Compound A MC
2
4517 WT wag31 OE 2.94±0.025 3.41±0.040 4.01±0.060 
     
Compound B MC
2
4517 WT 21.8±0.400 24.3±0.350 27.3±0.300 
Compound B MC
2
4517 Ribosome 
Silencing Factor OE 
22.1±0.650 24.4±0.650 27.3±0.700 
Compound B MC
2
4517 WT wag31 OE 20.1±0.650 22±0.800 24.2±1.050 
 
Table 3. Summary of EC50, MIC90 and MIC99 values obtained from whole cell growth inhibition 
assays.   The results shown above are the mean ± SE for two separate experiments 
 
 
Both compounds showed reduced EC50 and MIC values on Wag31 over-expression 
indicating that Wag31 is the target (Table 3). However, the reduction in values suggests 
that the drug induces some change in the protein that causes it to be toxic to the cell.  
 
3.5 Gel formation in the presence and absence of compound 
To understand whether the compound causes a change in the protein conformational 
equilibrium, shifting it towards its gelatinous phase, a comparative study was performed. 
Wag31 WT, Wag31 E206G mutant protein, Wag31 9-96 N terminal construct and 
Wag31 97-260 C terminal construct were expressed and purified from E. coli (3 Liters 
each). 
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The quantity of gel in the supernatant was quantified (Figure 21). The C terminal 
construct was entirely in the gel form and was loaded after diluting 20 fold on a gravity 
column. However, this did not yield any soluble, non-gelatinous protein. Therefore, we 
will consider only the first three constructs in this discussion. 
 
 
 
 
Figure 21. Relative amounts of gel in the supernatant after lysing the cells overexpressing the three 
Wag31 variants 
 
 
The purified proteins were then concentrated in the presence and absence of compound 
(7.5 fold Molar excess). Binding was examined visually by comparing the color 
Wag31 WT Wag31 E206G Wag31 8-96 N 
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concentration in the concentrated protein (left) versus the flow through (right) (Figure 
22). 
 
 
 
 
Figure 22. Protein concentrated in the presence of compound A (left) and the respective flow 
through (right) 
 
 
While both the WT and N terminal construct seem to bind the compound, the E206G 
mutant had a visual appearance similar to the flow through even when concentrated 
down to less than 200 µl. When comparing the gel formation in the presence and 
absence of compound, a similar pattern was observed (Figure 23). 
 
The compound increased the propensity of the protein to form gels. This was confirmed 
by measuring protein concentration. In the presence of the compound, a greater 
proportion of the protein favored gel formation. The gel is promiscuous and has a 
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tendency to trap most proteins within the mesh. It does not seem to discriminate between 
Glft2 (M. tb protein) and lysozyme in a pull down assay (Figure 24). 
 
 
 
 
 
Figure 23. Protein gel formed in the absence (left) and presence (right) of compound A 
 
 
Since the E206G mutant protein does not seem to form a gel once purified and does not 
appear to form a gel in the presence of the compound, this may provide a lead 
concerning the means of resistance in the MC
2
7000 mutants.  
 
Wag31 WT Wag31 E206G Wag31 8-96 N 
 42 
 
 
 
Figure 24. SDS gel separation of pull-down performed using the Wag31 gel as bait 
 
Lysozyme 
Glft2 
Wag31 
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CHAPTER IV  
MATERIALS AND METHODS 
 
4.1 Cloning, protein over-expression and purification 
The primers used for generating various constructs used in this study are detailed below: 
           Construct                            Primers 
1. Wag31 WT pet28(b)TEV F: 5'- GAA TTC CAT ATG CCG CTT ACA CCT 
GCC -3' 
R: 5'- CCC AAG CTT CTA GTT TTT GCC CCG 
GTT GAA TTG ATC -3' 
2. Wag31 WT p1602-dest 17 F: 5'- CGG GGT ACC ATG CCG CTT ACA CCT 
GCC -3' 
R: 5'- CCC AAG CTT CTA GTT TTT GCC CCG 
GTT GAA TTG ATC -3' 
3. Wag31 M. smegmatis 
ortholog MCSG7 
 
F: 5'- TAC TTC CAA TCC AAT GCC ATG CCG 
CTC ACA CCA G-3' 
R: 5'-TTA TCC ACT TCC AAT GTC AGT TGT 
TGC CGC GGT TG-3' 
4. Wag31 9-96 aa MCSG7 F: 5'- TAC TTC CAA TCC AAT GCC CAC AAT 
GTG GCG TTC AGT AAG CCG -3' 
R: 5'- TTA TCC ACT TCC AAT GTT AGT TCA 
TCC CCG CCG AGA C -3' 
5. Wag31 97-260 aa MCSG7 F: 5'- TAC TTC CAA TCC AAT GCC GAG GAA 
CAG GCC CTG AAG  -3' 
R: 5'-TTA TCC ACT TCC AAT GTT ACT AGT 
TTT TGC CCC GGT TGA ATT GAT C -3' 
6. Wag31 128-260 aa MCSG7 F: 5'-TAC TTC CAA TCC AAT GCC ATG CTG 
GCC GAT GCC CAA-3' 
R: 5'-TTA TCC ACT TCC AAT GTT ACT AGT 
TTT TGC CCC GGT TGA ATT GAT C -3' 
 
Table 4. List of PCR primers used to generate Wag31 constructs 
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The primers used for mutagenesis are detailed below: 
 
 Construct Primers 
1. Wag31T73A pet28(b)TEV F: 5'-GTT ACG CCG CAG GCC GCG CAG GCA 
ATC CCG GC-3' 
R: 5'-GCC GGG ATT GCC TGC GCG GCC TGC 
GGC GTA AC-3' 
2. Wag31T73E pet28(b)TEV F: 5'-GTT ACG CCG CAG GCC GAA CAG GCA 
ATC CCG GC-3' 
R: 5'-GCC GGG ATT GCC TGT TCG GCC TGC 
GGC GTA AC-3' 
 
3. Wag31E206G pet28(b)TEV F: 5'-CCA GCA GCG CGC GGT GCT TGG CGG 
CCG CCT CGA GCA GCT GCG-3' 
R: 5'-CGC AGC TGC TCG AGG CGG CCG CCA 
AGC ACC GCG CGC TGC TGG-3' 
 
Table 5. List of PCR primers used to generate Wag31 mutants 
 
 
The gene coding for wag31 was amplified by PCR USING M. tb H37Rv genomic DNA 
as the template (Table 4). After restriction digestion they were ligated into the pet 28(b) 
TEV vector (TEV modification courtesy: Dr. Manchi Reddy). In case of the MCSG 
vectors, we followed the protocol detailed by Eschenfeldt et al [39]. The Agilent 
QuikChange II Site-Directed Mutagenesis Kit was used to generate point mutations. 
Primers were designed using the PrimerX software (Table 5). The IspD pet 28 (b) vector 
was generously provided by Cory Thurman. All of the vectors were submitted to GTL to 
confirm the protein coding sequence. 
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The different vectors were transformed into BL21 (DE3) protein over-expression strain 
(Novagen). Overnight culture was prepared and diluted the next morning (1:500) in fresh 
LB medium containing 50 µg/ml Kanamycin or 100 µg/ml Carbenicillin for pet28 and 
MCSG7 vectors respectively. The cells were grown in a 37°C shaker. IPTG (isopropyl-
β-d-thiogalactopyranoside) was added to a final concentration of 1 mM when the culture 
reached an optical density at 600 nm (OD600) of 0.8. Induction was carried out for 20 h 
in an 18°C shaker.  
 
Wag31 WT p1602-dest 17 was transformed into MC
2
4517 cells. 3 ml cultures were 
grown at 37°C for a minimum of 2 days before diluting into fresh 7H9 media 
supplemented with 0.5% Glycerol, 0.05% Tween 80 and 0.5% Dextrose. 80 µg/ml of 
Hygromycin and 20 µg/ml of Kanamycin were added for selection. Cells were induced 
by the addition of 20% Acetamide to a final concentration of 0.2% when the O.D. 600 
reaches 1. 
 
The cells were re-suspended in a buffer containing 20 mM Tris pH 8.0, 500 mM NaCl 
and 2mM β-Mercaptoethanol (Tris pH 7.5 with 5% Glycerol in case of ISPD), Protease 
Inhibitor Cocktail EDTA free set V(Novagen) (500 µl/50ml of lysate), MgCl2 (final 
concentration 5 mM) and DNase (0.5 mg/ml for IspD, 12.5 mg/ml for wag31). The cells 
were then disrupted by sonication using a Branson Sonifier 450 (Branson Ultrasonics 
Corp.) and cell lysates were clarified by centrifugation at 16000 rpm for an hour. The 
supernatant was filtered using a 0.45 micron syringe filter and applied on a Nickel 
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affinity column. A step-wise or gradient application of Imidazole (10-500 Mm) yielded 
80% pure protein. This protein was then dialyzed overnight against low salt (50-150 
mM) buffer. IspD was subjected to an additional purification step before it could be used 
for enzyme assays. It was loaded on an SE75 gel filtration column and the dimer peak 
was pooled, concentrated and stored in 50 µl aliquots after flash freezing in liquid 
Nitrogen. Wag31 could be stored on ice in the refrigerator for 4 days. Proteins were 
concentrated using Corning Spin-X UF 10 kDa MWCO concentrators (Corning Inc.).  
 
4.2 Protein crystallization trials 
Crystal screening was performed using the vapor diffusion method in 96 well sitting 
drop plates (Intelliplate). The various solutions from the commercial and Lab-designed 
screens were dispensed and mixed with the protein solution using the Mosquito Crystal 
Robot (TTP Labtech). Optimization plates were set up using the hanging and sitting drop 
26 well plates as well as the micro-batch under-oil plates. For the latter both Al’s oil and 
Mineral oil were used to layer above the crystal drops. 
 
Crystals were screened for diffraction both at the home X-ray Source as well as at 
beamline 19 ID, Structural Biology Center, Advanced Photon Source (APS), Argonne 
National Laboratory (ANL). 
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4.3 Enzyme assays, screening and dose response curves 
The IspD enzyme assay was performed in 50 mM Tris pH 7.5 supplemented with 1 mM 
MgCl2. 60 nM ISPD, 0.1 U/ml IPPase, 0.06 U/ml PNP and 200 µM MESG was used. 1 
µl of DMSO was added in the control wells. The reaction was initiated by the addition of 
the substrates (50 µM MEP and 100 µM CTP). The total reaction volume was 50 µl.  
The solutions were dispensed using the CyBi®-Well vario liquid handling system 
(CyBio AG) into Greiner 384-well flat-bottomed plates. The reaction was monitored by 
reading the absorbance at 360 nm using the Thermo Scientific Multiskan GO plate 
reader (Thermo Fisher Scientific, Inc.). 
 
The Screening data was plotted on Microsoft Excel and compounds which generated 
absorbance values below 3X standard deviation were considered hits. Counter screens 
were performed with the hits in the absence of IspD to eliminate IPPase and PNP 
inhibitors.  
 
Dose response curves were generated by incubating the enzyme with a serial dilution of 
the hit compounds (0-200 µM) and then running the enzyme assay. The concentration 
and % Inhibition were then fit into the Hill plot equation on CDD to calculate IC50. 
 
4.4 Whole cell assays 
Whole cell viability assays are performed using Resazurin, a non-fluorescent dye that is 
converted to pink, fluorescent Resorufin via the reduction reactions that occur in 
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metabolically active cells. The fluorescence is read using 560EX nm/590EM nm filter 
settings on the FLUOstar Omega Plate Reader (BMG LABTECH). 
 
The whole cell assays were performed by incubating the cells (MC
2
7000, MC
2
4517 and 
Human Dermal Fibroblast (HDF) cells to evaluate cytotoxicity) with a serial dilution of 
the relevant compounds AT 37°C, followed by staining with Resazurin. The incubation 
times varied depending on the growth rate of the particular cell type. 
 
In the wag31 OE assay, the media was supplemented with inducer (acetamide) and 
antibiotic (Hygromycin and Kanamycin) in order to maintain protein over-expression. 
The fluorescence values were used to calculate % inhibition on Microsoft Excel. The 
concentration and % Inhibition were then fit into the Hill plot equation on CDD to 
calculate EC50, MIC90 and MIC99. 
 
4.5 Intrinsic fluorescence measurement 
Intrinsic Fluorescence was measured using 10 µM (final concentration) of protein 
suspended in 120 µl of 20 mM Tris pH 8.0, 50 mM NaCl buffer. The buffer was used to 
blank the instrument every 3-4 readings. The compound concentration was increased 
from 0.75 µM to 500 µM final concentration, doubling the concentration each time. 3 
readings were taken for each representative concentration. The fluorescence is read by 
excitation at 282 nm followed by scanning emission between 280 and 600 nm on the 
Cary Eclipse Spectrophotometer (Agilent).  
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4.6 Mutation studies 
The resistant mutant colonies were inoculated in fresh 7H9 media and the genomic DNA 
extracted as detailed by Larsen et al [40]. The wag31 protein coding sequence was then 
amplified by PCR using the wag31 WT primers and cloned into pet 28 (b) TEV vector. 
These were then sent for sequencing to GTL using the T7 promoter and terminator 
primers. 
 
The samples were also sent for whole genome sequencing at a later date to identify 
mutations outside the wasg31 coding sequence. 
 
4.7 Gel harvesting and pull-down assays 
The gel formed on concentrating the protein was harvested by cutting out the 
concentrator membrane with a blade and scraping it with a spatula. The scrapings were 
stored in PCR tubes on ice for up to 4 days. 
 
For pull-downs, the gel was incubated with the protein of interest in a 1:1 or 1:2 molar 
ratio for up to 20 minutes at 4°C. It was then washed with 5X buffer (volume) for up to 
one hour with shaking. The wash buffer was sucked out using a 1ml pipette. The gel was 
then run on an SDS gel to determine if any protein remained bound. The gel was stained 
using Coomassie Brilliant Blue. 
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4.8 Western blot and protein quantification 
Protein samples were run on an SDS gel and transferred on to a nitrocellulose 
membrane. The membrane was the probed using an anti-His antibody peroxidase 
conjugated (Mouse, Sigma). It was then incubated with peroxidase substrate to generate 
a colored band on the membrane. 
 
Protein was quantified using Bradford reagent and absorbance at 595 nm read on 
Carey50 UV/Vis Spectrophotometer. BSA was used as standard.  
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CHAPTER V  
SUMMARY AND CONCLUSION 
 
Mycobacterium tuberculosis presents a significant world health challenge with the 
emergence of strains resistant to both first and second line drugs. Identifying new lead 
molecules with alternate targets is the greatest need of this moment. This study details 
the study of two such targets. 
 
The first study employs a top-down approach, where IspD is first identified as a 
promising enzyme in an essential pathway. An assay was developed and then adapted to 
the medium-throughput 384-well format. The enzyme was then screened against various 
whole cell active molecules which included compounds from our diversity libraries, 
natural products, NIH approved small molecules and herbicides. Since these compounds 
are known to be whole-cell active, the challenging issue of breaching the M. tb cell wall 
is circumvented. Two compounds were identified by the screen with IC50s of 26.1 and 
37.8 µM and which were whole cell active at 50 µM concentrations. These could be lead 
molecules for the rational design of more potent IspD inhibitors.  
 
The study involving Wag31 employed a two-pronged approach. Wag31 was identified 
as a promising target, being both essential and without a homolog in the host and thus 
attempts were underway to characterize it and understand its function. Parallel studies 
conducted within the lab identified Wag31 as the target of one of the whole cell active 
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compounds in the SRI library. Point mutations within the Wag31 protein coding region 
of the M. tb and M. smegmatis genome conferred resistance to this compound. 
Furthermore, all the mutations were clustered within the C-terminal coiled-coil domain 
of the Wag31 protein coding sequence. Increasing the concentration of the compound 
incubated with Wag31 reduced the protein’s intrinsic fluorescence and concentrating in 
the presence of the compound increased the tendency of the protein to form a gel 
indicating that the compound interacts with the protein. Wag 31 protein that harbors the 
same mutation as those identified in the compound A resistant mutants did not form a 
gel on concentrating in the presence or absence of compound A suggesting that the lack 
of gel formation may explain the resistance. The over-expression of Wag31 in M. 
smegmatis caused a reduction in EC50 and MIC values. This points toward Wag31 being 
the true target of compound A in the cell and lends further credence to the idea that the 
compound causes some change in the protein that causes it to be toxic to the cell, i.e., gel 
formation. This represents a truly unique means of compound action in the 
Mycobacterial cell and one that must be investigated in detail. 
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APPENDIX 
 
Compounds that dropped out during the secondary screen against PNP and IPPase 
(IspD project) 
 
 
 
 60 
 
 
 61 
 
 
 62 
 
 
 63 
 
 
 64 
 
 
 
